Cargando…

Lanreotide Depot to Treat Gastroenteropancreatic Neuroendocrine Tumors in a US Community Oncology Setting: A Prospective, Observational Study

INTRODUCTION: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) can result in symptoms such as diarrhea, flushing, abdominal pain, and fatigue and are often associated with a significant disease burden and poor prognosis. This non-interventional, prospective, observational study evaluated the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Paulson, Scott, Ray, David, Aranha, Sharan, Scales, Amy, Wang, Yunfei, Liu, Eric
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9681944/ https://www.ncbi.nlm.nih.gov/pubmed/36136274 http://dx.doi.org/10.1007/s40487-022-00208-1

Ejemplares similares

Treatment with Lanreotide Depot Following Octreotide Long-Acting Release Among Patients with Gastroenteropancreatic Neuroendocrine Tumors
por: Saif, Muhammad Wasif, et al.
Publicado: (2018)

Clinical utility of lanreotide Autogel(®) in gastroenteropancreatic neuroendocrine tumors
por: Paragliola, Rosa Maria, et al.
Publicado: (2016)

Lanreotide Depot: An Antineoplastic Treatment of Carcinoid or Neuroendocrine Tumors
por: Wolin, Edward M., et al.
Publicado: (2016)

Lanreotide vs octreotide LAR for patients with advanced gastroenteropancreatic neuroendocrine tumors: An observational time and motion analysis
por: Ryan, P, et al.
Publicado: (2019)

Predictors of antiproliferative effect of lanreotide autogel in advanced gastroenteropancreatic neuroendocrine neoplasms
por: Laskaratos, Faidon-Marios, et al.
Publicado: (2019)

Current treatment options for gastroenteropancreatic neuroendocrine tumors with a focus on the role of lanreotide
por: Kos-Kudła, Beata, et al.
Publicado: (2017)

Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study
por: Caplin, Martyn E., et al.
Publicado: (2020)

Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial
por: Corti, Francesca, et al.
Publicado: (2023)

Co-Creation of a Lanreotide Autogel/Depot Syringe for the Treatment of Acromegaly and Neuroendocrine Tumours Through Collaborative Human Factor Studies
por: Adelman, Daphne T., et al.
Publicado: (2019)

Real world use of lanreotide in neuroendocrine tumors
por: Siddiqui, Zeba, et al.
Publicado: (2023)

Correction to: Co-Creation of a Lanreotide Autogel/Depot Syringe for the Treatment of Acromegaly and Neuroendocrine Tumours Through Collaborative Human Factor Studies
por: Adelman, Daphne T., et al.
Publicado: (2020)

Lanreotide depot deep subcutaneous injection: a new method of delivery and its associated benefits
por: Carmichael, John D
Publicado: (2012)

Monitoring and Surveillance of Patients with Gastroenteropancreatic Neuroendocrine Tumors Undergoing Radioligand Therapy
por: Halfdanarson, Thorvardur R., et al.
Publicado: (2023)

Novel Tumor Growth Rate Analysis in the Randomized CLARINET Study Establishes the Efficacy of Lanreotide Depot/Autogel 120 mg with Prolonged Administration in Indolent Neuroendocrine Tumors
por: Dromain, Clarisse, et al.
Publicado: (2021)

Tumour-to-liver ratio determined by [(68)Ga]Ga-DOTA-TOC PET/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumours
por: Kim, Yong-il, et al.
Publicado: (2020)

Advances in the treatment of gastroenteropancreatic neuroendocrine tumors
por: Kunz, Pamela L, et al.
Publicado: (2010)

Gastroenteropancreatic neuroendocrine tumors: diagnosis and treatment
por: Díez, Marc, et al.
Publicado: (2013)

Endoscopic Ultrasound in Gastroenteropancreatic Neuroendocrine Tumors
por: Kim, Michelle Kang
Publicado: (2012)

Medical Treatment of Gastroenteropancreatic Neuroendocrine Tumors
por: Rinke, Anja, et al.
Publicado: (2012)

Genetics and Epigenetics of Gastroenteropancreatic Neuroendocrine Neoplasms
por: Mafficini, Andrea, et al.
Publicado: (2019)

Exploring the Epigenome in Gastroenteropancreatic Neuroendocrine Neoplasias
por: Sharma, Rohini, et al.
Publicado: (2021)

Systemic Treatment of Gastroenteropancreatic Neuroendocrine Carcinoma
por: Mollazadegan, Kazhan, et al.
Publicado: (2021)

An update on the diagnosis of gastroenteropancreatic neuroendocrine neoplasms
por: Fang, Jiayun M, et al.
Publicado: (2022)

Epigenetic Regulation in Gastroenteropancreatic Neuroendocrine Tumors
por: Crabtree, Judy S.
Publicado: (2022)

Advances in the imaging of gastroenteropancreatic neuroendocrine neoplasms
por: Ramachandran, Anupama, et al.
Publicado: (2022)

Mechanisms of Resistance in Gastroenteropancreatic Neuroendocrine Tumors
por: Shi, Chanjuan, et al.
Publicado: (2022)

Liver transplantation in gastroenteropancreatic neuroendocrine tumors
por: Fernandes, Eduardo de Souza M., et al.
Publicado: (2023)

Therapy Resistant Gastroenteropancreatic Neuroendocrine Tumors
por: McClellan, Kristen, et al.
Publicado: (2022)

Budget impact of somatostatin analogs as treatment for metastatic gastroenteropancreatic neuroendocrine tumors in US hospitals
por: Ortendahl, Jesse D, et al.
Publicado: (2017)

Lanreotide Induces Cytokine Modulation in Intestinal Neuroendocrine Tumors and Overcomes Resistance to Everolimus
por: Sciammarella, Concetta, et al.
Publicado: (2020)

Gastroenteropancreatic neuroendocrine tumors in children and young adults
por: Khanna, Geetika, et al.
Publicado: (2007)

Diagnostic work-up of gastroenteropancreatic neuroendocrine tumors
por: Öberg, Kjell
Publicado: (2012)

Gastroenteropancreatic neuroendocrine neoplasms: genes, therapies and models
por: Kawasaki, Kenta, et al.
Publicado: (2018)

Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors
por: Cives, Mauro, et al.
Publicado: (2020)

Gastroenteropancreatic neuroendocrine neoplasms: A clinical snapshot
por: Fernandez, Cornelius J, et al.
Publicado: (2021)

Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Neuroendocrine Tumors in Routine Clinical Practice in Germany and Austria
por: Rinke, Anja, et al.
Publicado: (2021)

MON-022 Enhancing Patient Care: Co-Creation and Validation of a New and Improved Delivery System for Lanreotide Depot/Autogel and Its Evaluation by US Healthcare Professionals
por: Adelman, Daphne, et al.
Publicado: (2019)

Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive Review
por: Ilett, Emma Elizabeth, et al.
Publicado: (2015)

Clinical and Preclinical Advances in Gastroenteropancreatic Neuroendocrine Tumor Therapy
por: Crabtree, Judy S.
Publicado: (2017)

MicroRNA analysis of gastroenteropancreatic neuroendocrine tumors and metastases
por: Zimmermann, Nadine, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_aqado87p3t2pta41dt67i5hi19